- Home
- PARR vs AUPH Comparison
PARR vs AUPH Comparison
Compare PARR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PARR | AUPH |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PARR | AUPH |
|---|---|---|
| Price | $61.85 | $14.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $57.00 | $17.25 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1313.56 | ★ 5075.00 |
| EPS | ★ 7.16 | 2.07 |
| Revenue | ★ $2,443,066,000.00 | $283,055,000.00 |
| Revenue This Year | N/A | $16.53 |
| Revenue Next Year | $4.73 | $16.24 |
| P/E Ratio | $8.92 | ★ $6.75 |
| Revenue Growth | ★ 30.99 | 20.38 |
| 52 Week Low | $12.04 | $6.83 |
| 52 Week High | $66.75 | $16.54 |
Technical Indicators
Market Signals| Indicator | PARR | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.93 | 55.01 |
| Support Level | $34.55 | $14.56 |
| Resistance Level | N/A | $15.23 |
| Average True Range (ATR) | 3.56 | 0.50 |
| MACD | 0.46 | 0.04 |
| Stochastic Oscillator | 69.94 | 67.97 |
Price Performance
Historical ComparisonAbout PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.